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Diversity Rules {#sec1.1}
---------------

Eija PirinenUniversity of Helsinki, Finland

Vitamin B3 is a very powerful vitamin. I have realized this fact during the last 10 years I have been working on NAD^+^ precursor vitamin B3s. While I made a transition from a postdoc to an independent group leader, I had the privilege to follow the full drug discovery path of vitamin B3s in diverse model organisms: from *C. elegans* to cells, mice, and humans. I have seen vitamin B3 forms increase lifespan in worms, turn mice into marathon runners, boost NAD^+^ levels efficiently in cells, and now alleviate symptoms of progressive muscle disease in humans. I have always dreamed that my scientific work could improve patients' quality of life. Thus, our positive findings with niacin in mitochondrial myopathy patients feel like a dream come true. But what made it possible for me to achieve my dream? How has a shy girl who grew up in a remote countryside in Finland and was the first person in the family to earn a PhD degree been able to experience all this? There are various reasons: Finland's high-quality and free education system and gender equality policy, international collaborations between research groups, continuous and long-term research funding, and inspiring mentors, but most importantly the teamwork of committed basic scientists and clinicians. When working with people with different areas of expertise and passion for science, even a shy country girl can go beyond her limits.

I, Too, Belong in Science! {#sec1.2}
--------------------------

Inês MahúInstituto Gulbenkian de Ciência, Portugal

I struggled to select the focus of this personal text. I could write about being a first-generation academic and the difficulties of convincing family members about the relevance of basic research. Or the struggles of trying to be heard and establish collaborations as a young woman in academia. I even thought to explore the topic of my paper: obesity, a disease surrounded by such harmful stigma. I concluded that it is more important to share what makes my journey truly unique: I am disabled, physical and mentally. But my disabilities are not obvious, so I became extremely good at hiding them for fear of being judged as less capable than my non-disabled colleagues. I actually started my PhD in full health, but soon after, on my morning walk to the lab, I got hit by a speeding car. I woke up from a coma in a hospital bed and was told I would need multiple surgeries to be able to walk again and that the amnesia I felt was a consequence of a brain injury. It would then take over a year before doctors could assess the level of permanent damage I would have to live with: luckily, I did not lose any reasoning capacities, but many memories never came back and I now live with chronic pain due to several orthopedic problems. I am grateful to have had the support and the opportunity to continue pursuing my PhD, whose main work is featured in this issue. Becoming disabled did not prevent me from achieving success but reinforced my scientific self-confidence. More than ever, I feel worthy and I belong!

Unbox the Magic of Science {#sec1.3}
--------------------------

Katharina TimperUniversity Hospital of Basel, Switzerland

When I joined the group of Jens Brüning in 2014, it was like a dream come true: I got the opportunity to free-run ideas without any limit in a fantastic scientific environment with a warm, welcoming atmosphere. I had already had a strong interest in incretins for many years. Instantly, I fell in love with astrocytes, due to their diverse role in controlling brain function and because they were, back then, not yet in the center of investigation in the field of metabolism regulation.

Being a medical doctor, I always perceived it as very stimulating to work closely with natural scientists. Incredibly supportive mentors, wonderful colleagues, and collaborators along the way made me realize that it is my diverse background of patient-centered work in clinical routine, clinical studies, and lab research that not only makes my life so rich and is just deeply satisfying, but also allows me to add particular perspectives to scientific questions. I strongly believe that in research working with and in a diverse team and network is key: an open mind, love, and respect for your colleagues not only catalyze novel and surprising ideas, but essentially unbox the magic of science. Like in our present project, for which I had the chance to team up with Almudena---a warm-hearted person and brilliant PhD student sharing my passion for astrocyte biology. Team spirit made this project fly. This spirit is what I aim to pass on and cultivate in my own group, which I just recently started.

If Only Cajal Knew... {#sec1.4}
---------------------

Almudena del Rio MartinMax Planck Institute, Cologne, Germany

Why do I recall things better when I learn them right before turning in? Why are some people slimmer than others? These are some questions that I would wonder about as a teenager. In high school, I realized that many of the answers lie in biology. Hence, I started a bachelor's in biology in my hometown, Madrid. While finishing my degree, my father, a former biology student himself, showed me his bachelor's thesis comprising beautiful sketches of neurons with very distinct morphologies. This boosted my interested in neuroscience, which led me to take neurobiology modules, as well as a Master in neuroscience. Learning that the first Nobel Prize in Physiology and Medicine awarded to a Spanish compatriot had been garnered by Santiago Ramón y Cajal was a big inspiration for me. Out of all the aspects of neuroscience that I was exposed to, I became fascinated by neuroendocrinology. I remember being mind-boggled when I learned about the underrated role of astrocytes, which Cajal had already speculated about. Hence, I was delighted when Jens Brüning allowed me to bring together two of my passions by working with Katharina on deciphering the role of GLP-1 receptors within astrocytes in metabolism. It was incredible to find that GLP-1 has such a profound effect on astrocyte metabolism. I hope our findings will further increase the current interest in astrocytes and, deep down, wish many of these future studies to be spearheaded by young female scientists that pursue their dreams.

Redirecting to Estrone {#sec1.5}
----------------------

Manuel Picón-RuizUniversity of Granada, Spain

For decades, the research in the field of estrogen receptor-positive (ER+) breast cancer has focused on studying the role of estradiol. However, no attention has been directed to estrone, even though this disease has a much greater incidence after menopause---when estrone becomes the principal estrogen---and particularly in obese postmenopausal women, the cohort with the highest estrone levels. When I joined the laboratory of Joyce M. Slingerland at the University of Miami 7 years ago, I started to study the interconnections between the adipose tissue and breast cancer. Based on these preliminary studies, a review of the literature on the inverse association between obesity and ER+ breast cancer risk in pre- and postmenopausal women, and the analysis of public databases for the expression of different HSD17B enzymes and disease outcome, the hypothesis demonstrated in this research article came to my mind.

This publication is the result of my first project in the role of Principal Investigator, thanks to the support of the Susan G. Komen Foundation and the Marie Curie Actions. I want to acknowledge my mentor Joyce M. Slingerland for believing in my ideas and sharing with me her knowledge of laboratory and project management that has allowed me to acquire the skills needed to become an independent researcher, and the work of all the collaborators, with a special thanks to Rehana Qureshi for her work in the completion of the last results of the project.

New Insights in Estrogen Biology {#sec1.6}
--------------------------------

Rehana QureshiSylvester Cancer Center, University of Miami

During my doctoral training, I worked on breast cancer and how microRNAs could modulate epithelial to mesenchymal transition (EMT) to regulate breast cancer progression. Obesity and breast cancer are positively correlated in postmenopausal women. Therefore, during my postdoc at the University of Miami, I got involved in a study where we were interested in knowing how estrone differs from 17β-estradiol. The limited information we had was that estrone is a weak hormone and its function is still understudied. One of the pinnacle moments during this study was when we discovered how estrone promotes faster tumor formation in ER+ breast cancer than does 17β-estradiol, as this could explain why the incidence of ER+ breast cancer increases post menopause. Another critical point was when we found how estrone promotes inflammation in obese mice while 17β-estradiol inhibits it. In general, a high estrone:17β-estradiol ratio in post menopause drives inflammation and stimulates hormone-sensitive breast cancer initiation. This mechanism may also be relevant to other obesity-associated diseases, including diabetes, cardiovascular diseases, and neurodegenerative diseases such as Parkinson's and Alzheimer's, which increase in postmenopausal women. Our study therefore opens a new window for how estrone promotes ER+ cancer. I plan to continue exploring the effects of female hormones, especially how they affect postmenopausal women in the context of obesity.

Hijacking Immunometabolism {#sec1.7}
--------------------------

Sebastián A. Riquelme ColetColumbia University, New York

I always wondered how certain environmental pathogens can live for days, months, and even decades once inside our bodies. As these are not part of our regular flora, something exceptional must happen. As a postdoc at Columbia University, New York, I discovered that certain bacteria have evolved interesting mechanisms to persist even if surrounded by angry phagocytes. And it is such a story worth telling! In this issue of *Cell Metabolism* with my group, we demonstrate that, once inhaled into the lung, the bacterium *Pseudomonas aeruginosa* is massively attacked by different groups of macrophages, monocytes, and neutrophils. These myeloid gangs not only engulf incoming bacilli, they also release specific microbicidal immunometabolites to terminate with their existence. However, *P. aeruginosa* responds to this stress by producing biofilms. I never thought *P. aeruginosa* could thrive in such a negative environment by enjoying the "culinary skills" of our own defenses. How? Because *P. aeruginosa* adapts to consume these toxic metabolites as its preferred food. And this is not good for us at all, as our own phagocytes end up being top chefs that fuel *P. aeruginosa* chronic infection. In the era of limited strategies to clear long-term and multidrug-resistant infections, these findings are exciting, as they reveal what else we can target to potentially eradicate intractable pneumonia: immunometabolic pathways. This work contributed to my promotion as faculty in the same institution, and I foresee an interesting future studying how the burgeoning field of immunometabolism could provide us with new tools to better control infectious diseases.

Pursue Your Dreams {#sec1.8}
------------------

Vivian A. PaschoalUT Southwestern Medical Center, Dallas

I started working in a cell physiology laboratory during my first year of college, when I was just 18 years old. When I graduated from the nutrition program in my undergraduate school, I already had some years of experience in the laboratory. This experience, along with my major in nutrition, motivated me to join the field of obesity and diabetes research for PhD study.

I did my PhD at the University of São Paulo, Brazil. During the last year of my PhD, I was offered the opportunity to work in a prestigious lab at the University of California, San Diego (UCSD), where I could meet fantastic researchers like my current PI, Dr. Dayoung Oh. She recognized me beyond my language barrier, as a young researcher with great potential who is eager to learn. When she received an offer from Touchstone Diabetes Center, University of Texas Southwestern Medical Center (UTSW), she invited me to go on that journey together with her.

During these 6 years working together from UCSD to UTSW, we shared many interests as female scientists, and she always reminds me of "growing together"; we went through many challenges, collaborations, and projects, and I cannot express how flattered I am to publish together our recent research article, "Positive Reinforcing Mechanisms between GPR120 and PPARγ Modulate Insulin Sensitivity," in *Cell Metabolism*. I look forward to contributing even more research on GPCRs in obesity and diabetes.

I hope my journey so far can inspire other young researchers from around the globe to pursue their dreams.

Learning Along the Way {#sec1.9}
----------------------

Jing ZhangETH Zurich, Switzerland

The most exciting part of science is that one can always learn something new. During my bachelor's, I worked in a chemistry lab synthesizing compounds that target cancer. The literature from this field was largely focused on how to improve the synthesis process, but I always wondered *how* these compounds affect cancer growth and *whether* they have any side effects for the patients. I realized I needed to learn more about biology to answer my questions. After graduating from my bachelor program, I focused on understanding the molecular mechanisms by which compounds drive the formation of blood vessels. I transitioned to endothelial cell metabolism during my PhD under the supervision of Prof. De Bock. It has been exciting to have excellent colleagues with whom I can brainstorm about my project. Initially, we planned to do a small project to explore the role of endothelial *pfkfb3* during post-ischemic revascularization. However, once I got the first results, I realized that the phenotype could not be explained only by changes in endothelial metabolism. I noticed dramatic changes in the immune cells and was fascinated by the idea that endothelial cell-derived metabolites could affect the immune cells. Luckily, I had great collaborators to help me identify these effects and explore the interactions between endothelial cells and macrophages. This collaboration made it possible to efficiently complete a project that branched into a foreign field and taught me something new along the way.

A Full and Endless Experience {#sec1.10}
-----------------------------

Gaëlle MarenneInserm, Université Brest, France

I work in genetic epidemiology. As a child, I did not consider this for my future grown-up activity. This is for a simple reason: I did not even know such a thing existed! I realized this option as a student about to enter the professional world. I wanted to learn more, not to get into a routine by just applying what I learned at school. Research fulfilled my expectations. This is a continuous learning, understanding, innovating approach, with many opportunities to share, communicate, and collaborate about our work. This project, in particular, on finding genes involved in extreme early-onset obesity was an amazing opportunity for collaboration: diversity of backgrounds, experiences, and roles at the professional level; nationalities, cultures, and points of views at the personal level; and a chance for professional and personal enrichment. Lots of discussions generate lots of ideas. The first author's role is to explore these different ideas. Some of them are dead ends and parts of the work go to the bin; some open new directions and provide either small pieces of the response to some major issues of public health or other important fields of the society, or methods that are needed by the research community to complete other projects. It is difficult to say what will be the research directions of tomorrow, for this is rather more a winding than a linear path. When nice results come out, there is no doubt that it's worth all the work.

Cut the Sweet Nourishment of COVID-19 {#sec1.11}
-------------------------------------

Hongliang LiWuhan University, China

I have never been so sad as I am from witnessing the lives and livelihood being taken away from so many people so fast by the ravage of COVID-19 across the globe. It is now apparent that people with certain pre-existing comorbidities are more likely to die from COVID-19, especially those with hypertension, diabetes, and cardiovascular diseases. Considering that more than 2 billion individuals in the world are currently affected by some form of cardiometabolic disease, there is an urgent calling for us to understand how these underlying conditions adversely affect the outcome of COVID-19 progression. We have been dedicated to the endeavor of discovering new mechanisms and therapeutics of cardiometabolic diseases, and we feel especially obliged to address this important issue in order to reduce the human toll of the COVID-19 pandemic. Fortunately for us, in recent years, we have built a big-data clinical research team and infrastructure, including critical expertise in statistics and artificial intelligence, as well as a vast network of physicians from collaborating hospitals. These earlier investments afford us the capacity to achieve efficient and accurate data collection, annotation, integration, and sophisticated mining, which are well suited to untangle the connections among different clinical features and the outcome of COVID-19. Indeed, our most recent efforts have uncovered the important impact of blood glucose management on the outcomes of COVID-19 patients with diabetes. More importantly, the results demonstrate that controlling blood glucose within the range between 3.9 and 10 mmol/L may serve as an effective auxiliary approach to improve the prognosis of these patients. Such data-driven discoveries will guide our future studies on the pathogenesis of cardiometabolic diseases including, but not limited to, non-alcoholic fatty liver diseases, diabetes, and heart failure.
